2022
Inflammatory pathways and cholangiocarcioma risk mechanisms and prevention
Cadamuro M, Strazzabosco M. Inflammatory pathways and cholangiocarcioma risk mechanisms and prevention. Advances In Cancer Research 2022, 156: 39-73. PMID: 35961707, PMCID: PMC10916841, DOI: 10.1016/bs.acr.2022.02.001.Peer-Reviewed Original ResearchConceptsDevelopment of cholangiocarcinomaNonalcoholic fatty liver diseaseAdequate therapeutic treatmentPrimary sclerosing cholangitisFatty liver diseasePro-inflammatory mechanismsMain risk factorsProdromal diseaseSclerosing cholangitisCaroli's diseaseMetabolic syndromeChronic cholangiopathiesLiver diseasePoor prognosisInflammatory pathwaysBiliary treeCCA developmentRisk factorsImmune responseImmunological responseTherapeutic targetCholangiocarcinomaFluke infestationRole of cellExtrahepatic areas
2019
Fibrocystic Liver Disease
Cristoferi L, Morana G, Strazzabosco M, Fabris L. Fibrocystic Liver Disease. 2019, 201-218. DOI: 10.1007/978-3-319-96400-3_11.Peer-Reviewed Original ResearchHepatorenal fibrocystic diseaseCongenital hepatic fibrosisFibrocystic liver diseaseLiver diseaseCaroli's diseaseCholedochal cystEnd-stage liver diseaseBiliary duct dilationEmbryonic ductal plateAutosomal recessive polycystic kidney diseaseIntrahepatic bile ductsRecessive polycystic kidney diseasePolycystic kidney diseaseLiver transplantationDuct dilationHepatic involvementMultidisciplinary managementRenal diseaseMultiorgan involvementClinical manifestationsBile ductFibrocystic diseaseKidney diseaseBiliary treeHepatic fibrosis
2018
Fibroinflammatory Liver Injuries as Preneoplastic Condition in Cholangiopathies
Cannito S, Milani C, Cappon A, Parola M, Strazzabosco M, Cadamuro M. Fibroinflammatory Liver Injuries as Preneoplastic Condition in Cholangiopathies. International Journal Of Molecular Sciences 2018, 19: 3875. PMID: 30518128, PMCID: PMC6321547, DOI: 10.3390/ijms19123875.Peer-Reviewed Original ResearchConceptsMain molecular mechanismsDifferent lineagesPrimary sclerosing cholangitisMolecular mechanismsProfibrotic chemokinesNeoplastic transformationSclerosing cholangitisCaroli's diseaseOrgan dysfunctionChronic cholangiopathiesInflammatory infiltrateLiver injuryPeriportal fibrosisLiver diseaseInflammatory cellsProinflammatory cytokinesBiliary treePreneoplastic conditionsDifferent etiologiesTumor developmentMurine modelLiver responseParacrine fashionHepatic responseCellular types
2013
Protein kinase a‐dependent pSer675‐β‐catenin, a novel signaling defect in a mouse model of congenital hepatic fibrosis
Spirli C, Locatelli L, Morell CM, Fiorotto R, Morton SD, Cadamuro M, Fabris L, Strazzabosco M. Protein kinase a‐dependent pSer675‐β‐catenin, a novel signaling defect in a mouse model of congenital hepatic fibrosis. Hepatology 2013, 58: 1713-1723. PMID: 23744610, PMCID: PMC3800498, DOI: 10.1002/hep.26554.Peer-Reviewed Original ResearchConceptsAutosomal recessive polycystic kidney diseaseCongenital hepatic fibrosisCaroli's diseaseΒ-cateninHepatic fibrosisRac-1 inhibitionIntrahepatic bile ductsRecessive polycystic kidney diseasePotential therapeutic targetPolycystic kidney diseaseStimulation of cAMPRac-1 activityE-cadherin expressionBile ductKidney diseaseLiver pathologyCystic dysplasiaMouse modelTherapeutic targetTranscriptional activityNuclear translocationDiseasePKA blockerCholangiocytesFibrosis
2012
Polycystic liver diseases
Fabris L, McCrann C, Strazzabosco M. Polycystic liver diseases. 2012, 713-718. DOI: 10.1002/9781118321386.ch96.ChaptersPolycystic liver diseaseLiver diseaseCongenital hepatic fibrosisAutosomal dominant polycystic liver diseaseDifferent clinical entitiesChronic complicationsKidney involvementLiver transplantationPortal hypertensionCaroli's diseaseMedical therapyClinical entityLiver functionMultiple cystsSurgical approachHepatic fibrosisBiliary epitheliumHepatic parenchymaLiver parenchymaProgressive enlargementInterventional radiologyDiseaseGenetic defectsEndoplasmic reticulum-associated proteinParenchyma